Hispanic patients show a lower risk and longer time to a second cutaneous squamous cell carcinoma than matched non-Hispanic ...
Libtayo showed similar SPT rates to placebo but improved DFS in high-risk CSCC patients post-surgery and radiotherapy. The C-POST trial demonstrated Libtayo's superior DFS rates, with 81.1% at 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results